Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLORPRES vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLORPRES is a combination of clonidine (alpha-2 adrenergic agonist that reduces sympathetic outflow) and chlorthalidone (thiazide diuretic that inhibits sodium reabsorption in distal tubules).
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension
Hypertension
One tablet (clonidine 0.1 mg/chlorthalidone 15 mg) orally once or twice daily; maximum 0.6 mg clonidine/90 mg chlorthalidone daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life is 4-6 hours; may be prolonged in renal impairment, requiring dose adjustment.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Clonidine: hepatic metabolism (CYP2D6); Chlorthalidone: excreted unchanged in urine.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal excretion accounts for approximately 50% of elimination, with 30% as unchanged drug and 20% as metabolites; biliary/fecal elimination accounts for about 10%.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Approximately 90% bound to plasma proteins, primarily albumin.
~90%, primarily to albumin
0.8-1.0 L/kg, indicating extensive tissue distribution; higher Vd may correlate with prolonged effect.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral bioavailability is 60-70% due to first-pass metabolism; intravenous bioavailability is 100%.
Oral: 50–60% (extensive first-pass metabolism)
Chlorthalidone is ineffective if GFR <30 m L/min; avoid use. Clonidine requires dose reduction when GFR <10 m L/min; start at 0.1 mg once daily.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce clonidine dose by 25%. Child-Pugh C: avoid or use with extreme caution; clonidine may precipitate encephalopathy.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not recommended for children; safety and efficacy not established.
Not recommended for pediatric use; safety in children under 12 years not established.
Start with clonidine 0.1 mg chlorthalidone 15 mg once daily; monitor for orthostatic hypotension, bradycardia, and electrolyte disturbances. Titrate slowly every 2 weeks.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
Rebound hypertension with abrupt clonidine withdrawal,Hypokalemia due to chlorthalidone,Bradycardia and syncope,Renal impairment: monitor electrolytes
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to clonidine or chlorthalidone,Anuria,Severe bradycardia or heart block
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid high-sodium foods as they can counteract the antihypertensive effect. Limit alcohol intake. Chlorthalidone may cause potassium depletion; consider potassium-rich foods (bananas, oranges, spinach) unless contraindicated. Grapefruit juice may increase clonidine levels; avoid excessive intake.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
Pregnancy Category C. First trimester: risk of fetal bradycardia, oligohydramnios, and growth restriction due to reduced placental perfusion. Second/third trimester: potential for neonatal hypotension, respiratory depression, and electrolyte disturbances. Avoid use in pregnancy unless benefit outweighs risk.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Excreted in breast milk. M/P ratio not established. Monitor infant for bradycardia, hypotension, and hypoglycemia. Use caution; alternative agents preferred.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Dose adjustments may be required due to increased plasma volume and metabolism. Start at lowest effective dose; titrate based on blood pressure response and fetal status. No established specific dose changes.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Clorpres (clonidine + chlorthalidone) combines central alpha-2 agonist with thiazide diuretic. Monitor for orthostatic hypotension, especially in elderly. Rebound hypertension upon abrupt clonidine discontinuation is dangerous; taper over 2-4 days. Chlorthalidone may cause hypokalemia; check potassium levels regularly. Avoid use in patients with history of depression or severe bradycardia.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take the medication exactly as prescribed, usually once daily in the morning to prevent nighttime urination.,Do not stop taking this medication suddenly; stopping abruptly can cause a severe rise in blood pressure.,Rise slowly from sitting or lying down to prevent dizziness or fainting.,Avoid alcohol, which can worsen side effects like dizziness and drowsiness.,Report signs of low potassium (muscle cramps, weakness, irregular heartbeat) or dehydration (excessive thirst, dry mouth, dark urine).
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLORPRES vs ALDORIL 15, answered by our medical review team.
CLORPRES is a Antihypertensive Combination that works by CLORPRES is a combination of clonidine (alpha-2 adrenergic agonist that reduces sympathetic outflow) and chlorthalidone (thiazide diuretic that inhibits sodium reabsorption in distal tubules).. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLORPRES and ALDORIL 15 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLORPRES is: One tablet (clonidine 0.1 mg/chlorthalidone 15 mg) orally once or twice daily; maximum 0.6 mg clonidine/90 mg chlorthalidone daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLORPRES and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLORPRES is classified as Category C. Pregnancy Category C. First trimester: risk of fetal bradycardia, oligohydramnios, and growth restriction due to reduced placental perfusion. Second/third trimester: potential for . ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.